Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 25, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: September 22, 2006
- Previous Holding: 17,371,143 ADRs
- New Holding: 17,410,853 ADRs
- Average Price: $54.00
- Reason: Movement in the fund.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that the Plan is a discretionary fund for employees and former employees. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are potentially interested in the shares held in the fund in the same manner as other employees.
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan as of September 22, 2006 (17,410,853).
- Confirm the potential interest of Directors Dr. J P Garnier and Dr. M M Slaoui in the fund's holdings.
- Note that this filing is a notification under Disclosure Rule 3.1.4R(1)(b) and does not contain financial performance data.